Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies

NCT02597062 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02597062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02597062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2016
Completion date
February 1, 2022
Enrollment
76 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma